Orals

MK-677 (Ibutamoren) 12.5mg

Name: MK-677 (Ibutamoren) 12.5mg
Brand: Quanta Pharmaceuticals

A non-peptide ghrelin mimetic studied for raising growth hormone and IGF-1 for recovery and body composition.

MK-677 (Ibutamoren) is a non-peptide growth hormone secretagogue studied for its ability to stimulate the release of growth hormone and downstream IGF-1 through oral administration, rather than injection. This formulation supplies 60 tablets of 12.5mg per tub. Chemically classified as C27H36N4O, Ibutamoren works by mimicking the action of ghrelin at the GHS-R1a receptor, triggering a pulsatile release of growth hormone from the pituitary gland. In a frequently cited clinical study of older adults (Chapman et al.), daily administration raised 24-hour mean growth hormone output by roughly 97% and restored circulating IGF-1 to youthful-adult levels within weeks; other trials report a 40-72% sustained rise in IGF-1. A year-long trial in healthy older adults reported around 1.1kg of lean mass gained versus a 0.5kg loss in the placebo group, alongside increases in bone-turnover markers. With a half-life of approximately 24 hours, MK-677 supports sustained once-daily research dosing. It is not approved for any medical use in any jurisdiction and is included on WADA's list of prohibited substances.

Verify a product

Specifications

Tablets

Dose Per Tablet

12.5mg

Half-Life

24 hours

Administration

Oral

Chemical Structure

C27H36N4O

Research Benefits

Elevated Growth Hormone and IGF-1 — Clinical research reports roughly 97% higher 24-hour mean GH output and IGF-1 restored to young-adult levels within weeks of daily dosing.
Sustained IGF-1 Increase — Multiple human trials report a 40-72% sustained rise in circulating IGF-1.
Lean Mass Support — A year-long trial in older adults reported ~1.1kg of lean mass gained versus a 0.5kg loss on placebo.
Sleep Architecture — Studied for increasing slow-wave (deep) sleep by up to 50% and REM sleep by up to 20%.
Bone Turnover Markers — Research reports increases in osteocalcin and bone-specific alkaline phosphatase within 6-8 weeks.
Oral Bioavailability — A non-peptide structure allows meaningful GH-axis activation without injection.

How It Works

Ibutamoren is a non-peptide agonist at the GHS-R1a receptor, the same receptor targeted by the endogenous hormone ghrelin. By binding this receptor in the hypothalamus and pituitary, it triggers a pulsatile release of growth hormone that closely mimics the body's natural secretion pattern.

This growth hormone release drives a corresponding rise in circulating IGF-1, a pathway studied extensively for its downstream effects on protein synthesis, recovery, sleep architecture, and bone turnover. A roughly 24-hour half-life allows once-daily research dosing while maintaining consistent GH-axis stimulation. MK-677 remains an unapproved compound and is prohibited in competitive sport by WADA.

⚠ For Research Use Only

This product is supplied strictly for in-vitro laboratory and preclinical research use. It is not a drug, food, dietary supplement, or cosmetic, and is not intended for human or animal consumption, diagnosis, treatment, or prevention of any disease. MK-677 (Ibutamoren) 12.5mg must be handled only by qualified individuals trained in proper laboratory safety procedures.

By purchasing, the buyer confirms this product is being acquired for legitimate research purposes and assumes full responsibility for its handling, storage, and use in compliance with all applicable local, national, and international laws.